FDA approves supplemental efficacy application for AstraZeneca's TruqapSep 16Regulatory decisionAstraZenecacapivasertib
AstraZeneca posts CAPItello-281 results in PTEN-deficient prostate cancer; registers AZD4954 Phase 1Sep 10Weekly roundup, 2 itemsAstraZenecaAZD4954
AstraZeneca week: Imfinzi label update, ASSURE CLL results posted, four trials registeredSep 3Weekly roundup, 6 itemsacalabrutinibAstraZeneca
Relay Therapeutics files to sell up to $213 million more shares via TD CowenAug 6FinancingRelay Therapeutics, Inc.
Sign inSign in